Longevity Funds 2 LLC

About

The Longevity Fund A LETTER FROM LAURA DEMING THIS IS THE DECADE IN WHICH WE GET DRUGS FOR LONGEVITY INTO THE CLINIC Sept 2023 I started The Longevity Fund in 2011. Since then, we’ve funded some of the first companies in the space to IPO and get plausible drug candidates into patients (so far, all for age-related diseases, not longevity directly). We’re launching a new fund with a new name (excited to work with our new GP Alex Colville and team!), so I’ll summarize how I feel about the field on our old homepage. The longevity field will play out in 3 stages: Pioneers (2013 - 2023) : companies started in this decade show you can make financial returns building a longevity company, and get reasonable drug candidates to patients for specific age-related diseases. ‍ Dominant players (2023 - 2050) : I think we’ll see a wave of the best founders the field has ever seen. They’ll be prepared with the right resources to build the companies that 1) will go on to get the first approved longevity drugs (for age-related diseases, with ongoing plausibly successful trials for lifespan by the end of the decade) and 2) enter major biotech leagues ($10B+ valuations, enduring pharma co), and 3) scale to change how 50+ year olds plan their time and energy. ‍ Generic players (2050+) : developing drugs for longevity will feel as obvious and mainstream as developing drugs for cancer. The field will receive substantially more public and private funding. Large pharma companies will have teams working

Key Contact